Opinion

Video

Determining Which DTC Patients May Benefit from Systemic Therapy

Author(s):

Lori J. Wirth, MD,Francis Worden, MD

Hyunseok Kang, MD, discusses the importance of balancing toxicities and other factors when initiating first-line treatments for patients with refractory differentiated thyroid cancer (DTC), while emphasizing the need to set clear goals and communicate potential adverse reactions before allowing patients to make informed decisions.

Related Videos
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
5 KOLs are featured in this series.
Related Content
Breast Cancer | Image Credit: © Axel Kock – stock.adobe.com
December 11th 2024

Elacestrant Plus Abemaciclib Shows Efficacy in ER+/HER2– Advanced or Metastatic Breast Cancer

D. Ross Camidge, MD, PhD; Douglas Ney, MD, professor, neurology and neurosurgery, program director, Neurology Residency Program, vice-chair, Education, Department of Neurology, University of Colorado Cancer Center
October 23rd 2024

Patient Prioritization Is the Foundation for a Successful Neurologic Oncology Career: With D. Ross Camidge, MD, PhD; and Douglas Ney, MD

Neil P. Shah, MD, PhD
December 1st 2024

The Addition of Asciminib and Removal of Omacetaxine Mark Notable CML NCCN Guideline Updates

Jennie W. Taylor, MD, MPH, associate professor, clinical neurology, University of California, San Francisco, community engagement liaison, Neurologic Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center
October 10th 2024

FDA Approval Insights: Vorasidenib in IDH1/2+ Grade 2 Astrocytoma and Oligodendroglioma

Alan P. Venook, MD
November 25th 2024

Tislelizumab Pushes HCC Field Forward With 2024 NCCN Guideline Category 1 Recommendation

The University of California San Francisco
November 11th 2024

UC Regents Approve UCSF Proton Therapy Center for Cancer Care